Intrinsic modifiers of beta-lactam resistance in nosocomial Enterobacterales
Project Number5K08AI155830-04
Contact PI/Project LeaderLAZARUS, JACOB ERIC
Awardee OrganizationMASSACHUSETTS GENERAL HOSPITAL
Description
Abstract Text
Project Summary / Abstract
Increasing rates of antibiotic resistance in common bacterial pathogens threatens to reverse many
of the gains made in human health over the past century. This proposal details a research plan
designed to understand the basic biology of resistance to beta-lactam antibiotics in an important
group of Gram-negative pathogens, the Enterobacterales.
Aim 1 of this proposal concerns a novel, conserved protein that the candidate has discovered helps
mediate beta-lactam resistance in the Enterobacterales. Through targeted experimentation and
quantitative proteomics, the candidate will discover how this protein functions at the molecular
level. Aim 2A takes a broader focus, seeking to characterize how many mutations are necessary to
impart resistance in an important pathogen of hospitalized patients, Serratia marcescens. This is
important to determine, because if this sort of resistance is difficult to acquire, it may be prudent for
clinicians to use narrower, rather than broader antibiotics. Finally, in Aim 2B, the candidate strives
to identify proteins and pathways necessary for a kind of intrinsic resistance that a group of
Enterobacterales can utilize to become resistant to even the last-line carbapenem group of
beta-lactams. This approach has the potential to identify new antibiotic targets.
The candidate’s background includes training in biochemistry and eukaryotic cell biology, as well
as the clinical practice of infectious diseases. This Mentored Clinical Scientist Research Career
Development Award proposes additional training in genomics, proteomics, and transcriptomics
necessary for an independent career investigating clinically relevant problems in the prokaryotic
cell biology of antibiotic resistance. With the guidance of his co-mentors, the candidate will obtain
this additional training using both formal coursework and hands-on training utilizing the best of the
resources available at the Massachusetts General Hospital, Brigham and Women’s Hospital, and
Harvard Medical School.
Public Health Relevance Statement
Project Narrative
Antibiotic resistance in Gram-negative bacteria poses an urgent threat to human health. We will
investigate how a specific conserved protein mediates resistance to the cephalosporin group of
beta-lactam antibiotics, characterize how likely the important human pathogen, Serratia
marcescens, is to develop resistance to cephalosporins during treatment, and identify novel
proteins and pathways necessary for this kind of resistance.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AddressAffectAffinityAllelesAnti-microbial susceptibilityAntibiotic ResistanceAntibioticsBacteriaBindingBiochemistryBiologyCarbapenemsCategoriesCause of DeathCell Membrane PermeabilityCellsCellular biologyCephalosporin ResistanceCephalosporinsCessation of lifeClinicalCollectionCommunicable DiseasesCritical PathwaysDataDown-RegulationDrug DesignEnterobacter cloacaeEukaryotic CellGeneral HospitalsGeneticGenetic ScreeningGenomicsGoalsGram-Negative BacteriaHealthHospitalizationHospitalsHumanInfectionK-Series Research Career ProgramsKlebsiella aerogenesLearningMass Spectrum AnalysisMassachusettsMediatingMembraneMentorsModificationMolecularMutationOrganismPathway interactionsPatientsPeptidoglycanPersonsPredispositionProkaryotic CellsProteinsProteomicsResearchResearch PersonnelResistanceResistance developmentResourcesScientistSerratia marcescensSortingSystemTechniquesTestingTrainingVDAC1 geneWomanamidaseantibiotic resistant infectionsbeta-Lactam Resistancebeta-Lactamasebeta-Lactamscarbapenem resistant Enterobacteralescarbapenemasecareerclinical practiceclinically relevantcrosslinkderepressiondesignhealth care settingshuman pathogenimprovedin vivomedical schoolsmutantnoveloverexpressionpathogenpathogenic bacteriaperiplasmprotein functionresponsetranscriptomics
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
073130411
UEI
FLJ7DQKLL226
Project Start Date
15-December-2020
Project End Date
30-November-2025
Budget Start Date
01-December-2023
Budget End Date
30-November-2024
Project Funding Information for 2024
Total Funding
$199,702
Direct Costs
$185,000
Indirect Costs
$14,702
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$199,702
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5K08AI155830-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5K08AI155830-04
Patents
No Patents information available for 5K08AI155830-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5K08AI155830-04
Clinical Studies
No Clinical Studies information available for 5K08AI155830-04
News and More
Related News Releases
No news release information available for 5K08AI155830-04
History
No Historical information available for 5K08AI155830-04
Similar Projects
No Similar Projects information available for 5K08AI155830-04